BioSpace News Archive

On June 5, the FDA is expected to decide the fate of Acer Therapeutics’ experimental treatment for Urea Cycle Disorders (UCDs), ACER-001. CEO Chris Schelling spoke with BioSpace.

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

The FDA’s Vaccines and Related Biological Products Advisory Committee is set to review clinical data on June 7 and potentially suggest approval of NVX-CoV2373.

Warnings of Monkeypox went unheeded as scientists around the world began to uncover clues about the disease’s origin. Here are the latest updates on the monkeypox virus.

Pfizer announced the FDA has granted its combinatorial therapeutic ervogastat/clesacostat Fast Track Designation that is intended for the treatment of NASH with liver fibrosis.

At the 69th Annual Conference of the Israel Heart Society, UltraSight, and Sheba Medical Center Israel revealed new research findings from a blinded pilot study that validates the company’s technology, and confirms that UltraSight’s Artificial Intelligence (AI) guidance can allow any medical professional to successfully capture quality cardiac ultrasound images.

Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA ® (pembrolizumab) in Newly Diagnosed Glioblastoma.

A presentation at the upcoming annual meeting of the Infusion Nurses Society (INS) will discuss the recent development of a policy statement favoring low-level disinfection (LLD) as a safe and sufficient technique for disinfecting ultrasound transducers used in percutaneous procedures such as ultrasound-guided peripheral IV (UGPIV) catheter insertion.

Element Biosciences Inc., developer of the Element AVITI™ System, a new and disruptive DNA sequencing platform, announced that it has moved its headquarters to the Alexandria Tech Center located on the 37-acre, 14-building campus in the Sorrento Mesa life science hub of San Diego, California.

Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”) , a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that it has received European CE mark designation for its eLab S1 assay panel for use with a lithium heparinized whole blood sample.